BrightSpring Health Services Reports Strong Q1 Results and Raises 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: Newsfilter
- Financial Performance Growth: BrightSpring achieved net revenue of $3.614 billion in Q1 2026, a 25.6% increase year-over-year, indicating strong demand in the complex health services sector, which is expected to further enhance market share.
- Gross Margin Improvement: The company reported a gross profit of $482 million for Q1, up 42.5% from the same period in 2025, demonstrating significant progress in cost control and service efficiency, which will bolster profitability.
- Significant Net Income Increase: BrightSpring's net income reached $74 million in Q1, a substantial rise from $9 million in Q1 2025, reflecting successful strategies in operational efficiency and market positioning.
- 2026 Guidance Raised: The company has raised its full-year 2026 revenue guidance to between $14.725 billion and $15.225 billion, with expected growth rates of 14.1% to 17.9%, showcasing confidence in future market prospects and a strategic intent for continued expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTSG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTSG
Wall Street analysts forecast BTSG stock price to fall
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.430
Low
40.00
Averages
43.20
High
50.00
Current: 64.430
Low
40.00
Averages
43.20
High
50.00
About BTSG
BrightSpring Health Services, Inc. provides complementary home and community-based pharmacy and provides health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and rehab care, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. The Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. The Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Show Strong Stock Performance
- Butterfly Network Stock Surge: Butterfly Network's stock has risen 304% since publication, currently priced at $8.90, driven by the successful application of its Ultrasound-on-Chip technology and collaboration with Midjourney, with a full-body imaging system launch expected to boost market demand.
- Nuvectis Pharma Significant Progress: Nuvectis's NXP900 clinical program is advancing at top US hospitals, with a stock price increase of 104%, currently at $13.82, and preliminary data expected this summer, likely attracting investor interest.
- Trevi Therapeutics Clinical Trial Success: Trevi's Haduvio drug achieved positive results in the Phase 2b CORAL trial, with a stock price increase of 167%, currently at $17.21, and plans for two Phase 3 trials in 2026, indicating strong market potential.
- BrightSpring Health Service Growth: BrightSpring's stock has risen 291% since publication, currently priced at $66.25, as the company's operational and financial performance has drawn investor attention, with second-quarter results due in August, potentially revising 2026 revenue guidance upward.
See More
Four Stocks with Impressive Cash Flow Growth
- BrightSpring Health Services: The Zacks Consensus Estimate for BrightSpring's 2026 earnings has been revised upward by 10.6% to $1.67 over the past 60 days, indicating strong growth potential in the care of medically complex patients, particularly within Medicare and Medicaid markets.
- StoneX Group: StoneX's fiscal 2026 earnings estimate has increased by 13.9% to $6.00 per share over the past 60 days, reflecting enhanced execution capabilities and market demand in the financial services sector, thereby solidifying its market position.
- Cimpress plc: The earnings estimate for Cimpress for fiscal 2026 has improved by 5.2% over the past 30 days to $3.81 per share, showcasing sustained demand for high-quality customized products among small businesses and consumers, which strengthens its competitive edge.
- Flexsteel Industries: Flexsteel's fiscal 2026 earnings estimate has been revised upward by 2.8% to $4.78 per share in the past 30 days, demonstrating stable growth in the furniture design and manufacturing sector, particularly against the backdrop of rising demand in residential and commercial markets.
See More
Goldman Sachs Identifies High-Potential Stocks
- BrightSpring Health Services: Goldman Sachs initiated coverage with a buy rating and a $71 price target, highlighting its differentiated offerings in elder care that are expected to drive growth, with shares up 67% in 2026.
- Samsara Growth Potential: Analysts at Goldman Sachs view Samsara as one of the most defensible growth assets in software, anticipating improved profit margins, with shares rising 18% over the past month, recommending investors buy on any weakness.
- Ulta Beauty Market Share: Goldman Sachs believes Ulta is well-positioned to gain market share despite a 23% decline in stock this year, citing strong performance and share repurchase plans, with a target price of $652 indicating significant upside.
- Nvidia Investment Confidence: Goldman Sachs reiterated its buy rating on Nvidia, asserting that improved capital allocation will boost investor confidence, with growth expected to continue into 2027, with estimates over 30% above market expectations.
See More
Key Insights from Episode #443 of the Value Investor Podcast
- Value Stock Screening: Tracey Ryniec developed a screening tool that includes only Zacks #1 Rank (Strong Buy) stocks, with only 224 stocks currently meeting this criterion, indicating strong market confidence in these selections.
- BrightSpring Health Services: BrightSpring Health Services' stock has risen 68.8% year-to-date, with earnings expected to jump 67% in 2026, and a PEG ratio of 0.8, indicating both growth and value characteristics.
- Lifetime Brands Performance: Lifetime Brands' stock soared 125% in 2026, despite expected earnings falling 9.9% this year, yet it maintains an attractive forward P/E of 12.4 and a PEG ratio of 0.9, suggesting continued investment appeal.
- Phillips 66 Value: Phillips 66's stock is up 39% year-to-date, with earnings projected to rise 177% this year, a forward P/E of just 10, and a recent 7% increase in quarterly dividends, highlighting its deep value proposition.
See More
Latest Wall Street Ratings Overview
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
BrightSpring Health Services Announces Pricing of Secondary Offering
- Offering Details: BrightSpring Health Services has priced a secondary offering of 15 million shares at $58.75 each, with all proceeds going to the selling stockholders, indicating strong market activity and shareholder confidence.
- Shareholder Dynamics: The offering involves selling stockholders including Kohlberg Kravis Roberts & Co. L.P. and certain management members, reflecting management's confidence in future growth and potentially altering shareholder dynamics.
- Repurchase Plan: Following the offering, BrightSpring plans to repurchase 1,026,694 shares from the underwriter at the same price as the offering, demonstrating the company's recognition of its stock value and a proactive market stance.
- Underwriter Role: Goldman Sachs is acting as the sole book-running manager for the offering, highlighting its significant position in the capital markets while providing professional support to BrightSpring, thereby enhancing investor confidence.
See More
Multiple Companies Show Strong Stock Performance
- Butterfly Network Stock Surge: Butterfly Network's stock has risen 304% since publication, currently priced at $8.90, driven by the successful application of its Ultrasound-on-Chip technology and collaboration with Midjourney, with a full-body imaging system launch expected to boost market demand.
- Nuvectis Pharma Significant Progress: Nuvectis's NXP900 clinical program is advancing at top US hospitals, with a stock price increase of 104%, currently at $13.82, and preliminary data expected this summer, likely attracting investor interest.
- Trevi Therapeutics Clinical Trial Success: Trevi's Haduvio drug achieved positive results in the Phase 2b CORAL trial, with a stock price increase of 167%, currently at $17.21, and plans for two Phase 3 trials in 2026, indicating strong market potential.
- BrightSpring Health Service Growth: BrightSpring's stock has risen 291% since publication, currently priced at $66.25, as the company's operational and financial performance has drawn investor attention, with second-quarter results due in August, potentially revising 2026 revenue guidance upward.
See More
Four Stocks with Impressive Cash Flow Growth
- BrightSpring Health Services: The Zacks Consensus Estimate for BrightSpring's 2026 earnings has been revised upward by 10.6% to $1.67 over the past 60 days, indicating strong growth potential in the care of medically complex patients, particularly within Medicare and Medicaid markets.
- StoneX Group: StoneX's fiscal 2026 earnings estimate has increased by 13.9% to $6.00 per share over the past 60 days, reflecting enhanced execution capabilities and market demand in the financial services sector, thereby solidifying its market position.
- Cimpress plc: The earnings estimate for Cimpress for fiscal 2026 has improved by 5.2% over the past 30 days to $3.81 per share, showcasing sustained demand for high-quality customized products among small businesses and consumers, which strengthens its competitive edge.
- Flexsteel Industries: Flexsteel's fiscal 2026 earnings estimate has been revised upward by 2.8% to $4.78 per share in the past 30 days, demonstrating stable growth in the furniture design and manufacturing sector, particularly against the backdrop of rising demand in residential and commercial markets.
See More
Goldman Sachs Identifies High-Potential Stocks
- BrightSpring Health Services: Goldman Sachs initiated coverage with a buy rating and a $71 price target, highlighting its differentiated offerings in elder care that are expected to drive growth, with shares up 67% in 2026.
- Samsara Growth Potential: Analysts at Goldman Sachs view Samsara as one of the most defensible growth assets in software, anticipating improved profit margins, with shares rising 18% over the past month, recommending investors buy on any weakness.
- Ulta Beauty Market Share: Goldman Sachs believes Ulta is well-positioned to gain market share despite a 23% decline in stock this year, citing strong performance and share repurchase plans, with a target price of $652 indicating significant upside.
- Nvidia Investment Confidence: Goldman Sachs reiterated its buy rating on Nvidia, asserting that improved capital allocation will boost investor confidence, with growth expected to continue into 2027, with estimates over 30% above market expectations.
See More
Key Insights from Episode #443 of the Value Investor Podcast
- Value Stock Screening: Tracey Ryniec developed a screening tool that includes only Zacks #1 Rank (Strong Buy) stocks, with only 224 stocks currently meeting this criterion, indicating strong market confidence in these selections.
- BrightSpring Health Services: BrightSpring Health Services' stock has risen 68.8% year-to-date, with earnings expected to jump 67% in 2026, and a PEG ratio of 0.8, indicating both growth and value characteristics.
- Lifetime Brands Performance: Lifetime Brands' stock soared 125% in 2026, despite expected earnings falling 9.9% this year, yet it maintains an attractive forward P/E of 12.4 and a PEG ratio of 0.9, suggesting continued investment appeal.
- Phillips 66 Value: Phillips 66's stock is up 39% year-to-date, with earnings projected to rise 177% this year, a forward P/E of just 10, and a recent 7% increase in quarterly dividends, highlighting its deep value proposition.
See More
Latest Wall Street Ratings Overview
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
BrightSpring Health Services Announces Pricing of Secondary Offering
- Offering Details: BrightSpring Health Services has priced a secondary offering of 15 million shares at $58.75 each, with all proceeds going to the selling stockholders, indicating strong market activity and shareholder confidence.
- Shareholder Dynamics: The offering involves selling stockholders including Kohlberg Kravis Roberts & Co. L.P. and certain management members, reflecting management's confidence in future growth and potentially altering shareholder dynamics.
- Repurchase Plan: Following the offering, BrightSpring plans to repurchase 1,026,694 shares from the underwriter at the same price as the offering, demonstrating the company's recognition of its stock value and a proactive market stance.
- Underwriter Role: Goldman Sachs is acting as the sole book-running manager for the offering, highlighting its significant position in the capital markets while providing professional support to BrightSpring, thereby enhancing investor confidence.
See More
